Other Information
+Added: Trading Arrangements
+Added: During the three months ended June 30, 2024, certain of our directors and/or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below.
+Added: Type of Trading Arrangement
+Added: Name and Position
+Added: Adoption/ Termination
+Added: Rule 10b5-1**
+Added: Total Shares of Common Stock to be Sold
+Added: Expiration Date
+Added: September 25, 2025
+Added: September 17, 2025
+Added: Alejandro Dorenbaum, M.D.
+Added: September 18, 2025
+Added: * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
+Added: ** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.
EXHIBIT INDEX
+Added: Agreement and Plan of Merger, dated May 10, 2024, by and among the Registrant, Radiate Merger Sub I, Inc., Radiate Merger Sub II, LLC and OnKure, Inc.
+Added: (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on May 13, 2024).
Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on April 13, 2021).
4 unchanged sentences
333-254534), filed with the SEC on March 19, 2021).
+Added: Subscription Agreement, dated May 10, 2024 (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K, filed with the SEC on May 13, 2024).
+Added: Consulting Agreement, dated May 10, 2024, by and between the Registrant and Gregory J.
+Added: Consulting Agreement, dated May 10, 2024, by and between the Registrant and Alejandro Dorenbaum, M.D.
+Added: Consulting Agreement, dated May 10, 2024, by and between the Registrant and Michael P.
+Added: Consulting Agreement, dated May 10, 2024, by and between the Registrant and Ashley F.
+Added: Form of Reneo Support Agreement (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on May 13, 2024).
+Added: Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K, filed with the SEC on May 13, 2024).
Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
5 unchanged sentences
Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
+Added: * Certain exhibits and/or schedules (and similar attachments) have been omitted pursuant to the provisions of Regulation S-K, Item 601(a)(5).
+Added: The Registrant hereby undertakes to furnish supplementally to the SEC upon request by the SEC copies of any of the omitted exhibits and schedules (or similar attachments).
** The certification attached as Exhibit 32.1 accompanies this Quarterly Report on Form 10-Q pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
+Added: + Indicates management contract or compensatory plan.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
+Added: August 13, 2024
RENEO PHARMACEUTICALS, INC.
6 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.